Cullen Frost Bankers Inc. Buys 8,437 Shares of The Clorox Company $CLX

Cullen Frost Bankers Inc. increased its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 18.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,833 shares of the company's stock after acquiring an additional 8,437 shares during the quarter. Cullen Frost Bankers Inc.'s holdings in Clorox were worth $6,464,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Fiduciary Family Office LLC boosted its stake in Clorox by 4.3% during the second quarter. Fiduciary Family Office LLC now owns 5,059 shares of the company's stock worth $607,000 after acquiring an additional 207 shares in the last quarter. Liberty One Investment Management LLC boosted its stake in Clorox by 11.5% during the second quarter. Liberty One Investment Management LLC now owns 224,873 shares of the company's stock worth $27,000,000 after acquiring an additional 23,132 shares in the last quarter. Triton Financial Group Inc bought a new position in Clorox during the second quarter worth $869,000. Journey Advisory Group LLC boosted its stake in Clorox by 22.1% during the second quarter. Journey Advisory Group LLC now owns 1,991 shares of the company's stock worth $239,000 after acquiring an additional 360 shares in the last quarter. Finally, Bogart Wealth LLC raised its holdings in Clorox by 289.5% during the second quarter. Bogart Wealth LLC now owns 370 shares of the company's stock worth $44,000 after buying an additional 275 shares during the last quarter. 78.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Jefferies Financial Group lowered their price objective on shares of Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Weiss Ratings restated a "hold (c-)" rating on shares of Clorox in a report on Tuesday, October 14th. JPMorgan Chase & Co. lowered their price objective on shares of Clorox from $135.00 to $127.00 and set a "neutral" rating on the stock in a report on Friday, October 10th. Zacks Research upgraded shares of Clorox from a "strong sell" rating to a "hold" rating in a report on Monday, September 29th. Finally, TD Cowen lowered their price objective on shares of Clorox from $120.00 to $117.00 and set a "hold" rating on the stock in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Buy rating, twelve have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Reduce" and an average price target of $130.20.

Clorox Stock Performance

Shares of CLX stock opened at $118.14 on Thursday. The firm has a 50-day moving average of $121.41 and a 200-day moving average of $127.30. The company has a market cap of $14.39 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.99 and a beta of 0.52. The company has a debt-to-equity ratio of 5.15, a current ratio of 0.84 and a quick ratio of 0.57. The Clorox Company has a one year low of $116.53 and a one year high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.24 by $0.63. The company had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities research analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be given a dividend of $1.24 per share. The ex-dividend date is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.2%. Clorox's dividend payout ratio is presently 76.07%.

Insiders Place Their Bets

In related news, COO Eric H. Reynolds sold 15,041 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the completion of the transaction, the chief operating officer owned 54,221 shares in the company, valued at approximately $6,711,475.38. This represents a 21.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.63% of the company's stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.